Identifying Patients With Unrecognized Treatable Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Registration Number
- NCT01934920
- Lead Sponsor
- Elman Retina Group
- Brief Summary
This trial will assess the incidence of new and/or undiagnosed diabetic macular edema (DME) in diabetic patients that undergo a DME screening exam. The screening exam will consist of medical history, Electronic ETDRS visual acuity assessment, SD-OCT and color fundus photography
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age > 18 years
- Patient related considerations
- Patients with diabetes mellitus
- Disease related considerations
- Diabetes mellitus
- Prior admission screening within twelve months.
- Inability to sit for evaluation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assess the incidence of new and/or undiagnosed diabetic macular edema. 1 day (Patients are only seen once for assessments) This trial will assess the incidence of new and/or undiagnosed diabetic macular edema (DME) in diabetic patients that undergo a DME screening exam. The screening exam will consist of medical history, Electronic ETDRS visual acuity assessment, SD-OCT and color fundus photography
- Secondary Outcome Measures
Name Time Method Streamlining and identification of patients at risk of diabetic macular edema 1 day (Patients only seen once for assessments) Establish methods for streamlining screening and identification of patients at risk.
Establish methods for referral for treatment of patients identified with vision threatening diabetic retinopathy.
Trial Locations
- Locations (2)
Aaron Goldberg, Primary Care
🇺🇸Baltimore, Maryland, United States
MedStar Hospital
🇺🇸Baltimore, Maryland, United States